Ask AI
ProCE Banner Activity

Expanding Options in CLL/SLL: What Hematology/Oncology Nurses Need to Know

Slideset

Downloadable slides from an ONS virtual webinar equipping hematology/oncology nurses with up-to-date knowledge managing CLL/SLL across frontline and relapsed/refractory settings, including treatment selection, emerging therapies, and patient-centered care strategies. The slides also emphasize practical nursing considerations such as adverse event management, treatment adherence, patient education, and interdisciplinary coordination. 

Released: March 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from BeOne Medicines USA Inc. and Lilly.

BeOne Medicines USA Inc.

Lilly

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, oncology nurses, and other healthcare professionals involved in the management of CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain targeted agents to patients with CLL/SLL according to their rationale, mechanisms of action, efficacy, and adverse event profiles 

  • Support patients’ goals and preferences when receiving treatment for newly diagnosed or relapsed/refractory CLL/SLL, considering prognostic variables, comorbidities, duration, and toxicity profiles

  • Evaluate current and emerging efficacy and safety evidence for the use of targeted agents, including CAR T-cells, in first-line, second-line, and later-line treatment of CLL/SLL

  • Identify and manage adverse events associated with targeted agents for CLL/SLL to improve duration on treatment and clinical outcomes

  • Use enhanced communication strategies to support patient engagement in care, including strategies to recognize and address adverse events, drug interactions, and treatment adherence